Dotatate gallium Ga-68
Also known as: 68Ga-DOTATATE, 68Ga‑DOTATATE, DOTA-Tyr3-octreotate Ga-68, DOTA‑TATE, Ga-68 DOTATATE, gallium-68 dotatate, Netspot
Source Dotatate gallium Ga-68 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Gallium Ga-68 dotatate (Netspot) is an FDA-approved PET imaging agent used for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adults and pediatric patients (≥2 years). It consists of the somatostatin analogue DOTA-Tyr3-octreotate chelated to the radiometal gallium-68 and provides superior sensitivity and resolution compared to conventional somatostatin receptor scintigraphy (octreotide scan).
Mechanism of Action
Dotatate (DOTA-Tyr3-octreotate) is a somatostatin analogue that binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on neuroendocrine tumor cells. When labeled with gallium-68 (a positron-emitting radionuclide), the conjugate enables positron emission tomography (PET) imaging of SSTR2-expressing tumors by localizing to tumor tissue and emitting positrons detectable by PET scanner.
Routes of Administration
Goals & Uses
- Staging and restaging of NETsDiagnostic OncologyHigh
- Localization of somatostatin receptor-positive neuroendocrine tumorsDiagnostic ImagingHigh
- Monitoring response to somatostatin analogue therapyTreatment MonitoringModerate
- Detection of occult primary NETDiagnostic ImagingModerate
- Patient selection for PRRT (peptide receptor radionuclide therapy)Treatment PlanningHigh
- Detect and stage somatostatin receptor‑positive neuroendocrine tumorsDiagnostic ImagingHigh
Contraindications
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- BreastfeedingPopulationModeratePotential transfer into breast milk or insufficient safety data
- Known hypersensitivity to DOTATATE or any excipientAllergyHigh
- Hypersensitivity to dotatate or any component of the formulationAllergyHigh
Adverse Effects
- Radiation exposureRadiologicalCommon
- Injection site painLocalCommonPain at the injection site
- Hypersensitivity/anaphylaxisImmunologicalRare
- Injection site pain/irritationLocalUncommon
- Hypersensitivity reactionImmunologicRare
- FlushingVascularUncommonWarmth and redness of the skin
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
Drug Interactions
- Long-acting somatostatin analogues (e.g., octreotide LAR, lanreotide)Moderate
- none identifiedLow
- Short-acting octreotideLow
Population Constraints
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveAbsolute
- Pediatric patients <2 yearsAgeRelative
Regulatory Status
- European UnionApprovedApproved: Imaging of somatostatin receptor‑positive neuroendocrine tumorsApproved under EU regulatory framework.
- United StatesApprovedApproved: Imaging of somatostatin receptor‑positive neuroendocrine tumorsApproved as NETSPOT.
- United KingdomApprovedApproved: Imaging of somatostatin receptor‑positive neuroendocrine tumorsApproved by MHRA.
FDA‑approved (NETSPOT) for diagnostic imaging of somatostatin receptor‑positive neuroendocrine tumors.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Dotatate gallium Ga-68?
Gallium Ga-68 dotatate (Netspot) is an FDA-approved PET imaging agent used for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adults and pediatric patients (≥2 years). It consists of the somatostatin analogue DOTA-Tyr3-octreotate chelated to the radiometal gallium-68 and provides superior sensitivity and resolution compared to conventional somatostatin receptor scintigraphy (octreotide scan).
What is Dotatate gallium Ga-68 used for?
Dotatate gallium Ga-68 is educationally associated with: Staging and restaging of NETs, Localization of somatostatin receptor-positive neuroendocrine tumors, Monitoring response to somatostatin analogue therapy, Detection of occult primary NET, Patient selection for PRRT (peptide receptor radionuclide therapy), Detect and stage somatostatin receptor‑positive neuroendocrine tumors. Educational only — not medical advice.
How is Dotatate gallium Ga-68 administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Dotatate gallium Ga-68?
Reported adverse effects include: Radiation exposure, Injection site pain, Hypersensitivity/anaphylaxis, Injection site pain/irritation, Hypersensitivity reaction, Flushing, Nausea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dotatate gallium Ga-68?
Recorded contraindications: Pregnancy, Breastfeeding, Known hypersensitivity to DOTATATE or any excipient, Hypersensitivity to dotatate or any component of the formulation. Consult a qualified clinician before use.